UCART123
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Trial Timeline
Jun 28, 2017 → Jun 27, 2019
NCT ID
NCT03203369About UCART123
UCART123 is a phase 1 stage product being developed by Cellectis for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The current trial status is terminated. This product is registered under clinical trial identifier NCT03203369. Target conditions include Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
What happened to similar drugs?
2 of 13 similar drugs in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) were approved
Approved (2) Terminated (3) Active (9)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04106076 | Phase 1 | Withdrawn |
| NCT03203369 | Phase 1 | Terminated |
Competing Products
20 competing products in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)